Hepatology Highlights
Clara Tow, Robert S. Brown, Zaid Husni Tafesh, Robert E. Schwartz, Russell Rosenblatt, Shawn L. Shah, Nicole T. Shen, Aleksey Novikov, Shirley Cohen‐Mekelburg, Nicholas Russo, Vikas Gupta – 20 November 2017
Clara Tow, Robert S. Brown, Zaid Husni Tafesh, Robert E. Schwartz, Russell Rosenblatt, Shawn L. Shah, Nicole T. Shen, Aleksey Novikov, Shirley Cohen‐Mekelburg, Nicholas Russo, Vikas Gupta – 20 November 2017
20 November 2017
Youliang Pei, Xiao‐ping Chen, Wanguang Zhang – 20 November 2017
Esther Nuñez‐Durán, Mariam Aghajan, Manoj Amrutkar, Silva Sütt, Emmelie Cansby, Sheri L. Booten, Andrew Watt, Marcus Ståhlman, Norbert Stefan, Hans‐Ulrich Häring, Harald Staiger, Jan Borén, Hanns‐Ulrich Marschall, Margit Mahlapuu – 20 November 2017 – Nonalcoholic fatty liver disease (NAFLD) contributes to the pathogenesis of type 2 diabetes and cardiovascular disease, and patients with nonalcoholic steatohepatitis (NASH) are also at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma.
Chetan Kalal, Akash Shukla, Ravi Mohanka, Mihir Vora, Priyesh Patel, Samir Shah – 20 November 2017
Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih‐Wei Lin, Yang Lei, Teresa I. Ng, Preethi Krishnan, Sarah Kopecky‐Bromberg, Jens Kort, Federico J. Mensa – 20 November 2017 – Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options.
20 November 2017
Tracey G. Simon, Lindsay Y. King, Dawn Q. Chong, Long H. Nguyen, Yanan Ma, Trang VoPham, Edward L. Giovannucci, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Hamed Khalili, Raymond T. Chung, Xuehong Zhang, Andrew T. Chan – 20 November 2017 – Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk.
Vian Azzu, Joshua E. Elias, Adam Duckworth, Susan Davies, Rebecca Brais, Dinakantha S. Kumararatne, Alexander E. S. Gimson, William J. H. Griffiths – 20 November 2017 – Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency characterized by antibody deficiency, recurrent bacterial infections, and autoimmunity. Advanced chronic liver disease occurs in a subset of patients with CVID and manifests with various histological features, such as nodular regenerative hyperplasia, inflammation, fibrosis, and cholangiopathy.
20 November 2017